Abstract: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.

Abstract: A composition comprising from 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil selected from the group consisting of anise oil, clove oil, cassia oil, cinnamon oil, and combinations thereof, wherein said composition is an ophthalmically acceptable emulsion is disclosed herein.

Abstract: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.

Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.

Abstract: Cyclosporin A compositions are disclosed herein comprising an oil and a surfactant.

Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.

Abstract: Systems and methods for utilizing metadata embedded in a color measurement target to uniquely identify the target through color measurement. A color measurement target is used for color calibration, color characterization, color adjustment and/or color correction of a color output device and includes a collection of color patches imaged by the output device, wherein metadata is embedded directly into the color patches of the color measurement target to uniquely identify the target through color measurement. The metadata-bearing patches in the target are used to communicate information through color measurement, and can contribute to the color characterization.

Abstract: Disclosed herein are methods of delivering drugs or therapeutically active agents to the back of the eye via topical administration of compositions comprising cyclodextrin derivatives. Compositions related thereto are also disclosed herein.

Abstract: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.

Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.

Abstract: A medical device provided with at least a partial surface coating of a thermoplastic copolymer of tetrafluoroethylene and perfluoroalkylvinylether that is free of cross-linking monomers and curing agents. The fluoropolymer coating is preferably an amorphous thermoplastic, is highly inert and biocompatible, has elastomeric characteristics that provide desirable mechanical properties such as good flexibility and durability. These characteristics allow the coating to be considered “functionally transparent” because it withstands mechanical deformations required for the assembly, deployment, expansion, and placement of medical devices, without any adverse effect on the mechanical and biological functionality of the coated device. Further, its inertness, derived from the perfluorocarbon structure, contributes to its functionally transparent nature.

Abstract: Embodiments of the present invention comprise methods and systems for color gamut mapping.

Abstract: Biocompatible microparticles include an ophthalmically active alpha-2 adrenergic receptor agonist and a biodegradable polymer. The microparticles include oil-in-water emulsified microparticles which can be used to treat an ocular condition, such as glaucoma.

Abstract: Triamcinolone compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.

Abstract: Waveguide based connector systems for optically coupling a fiber optic cable and an optoelectronic device and a method of fabricating the same are described. In one aspect, a connector system comprises an optical waveguide and an optical turn assembly. The optical waveguide has a first end and a second end. The first end of the optical waveguide is connectable to the fiber optic cable in an orientation aligned with a line-side connection axis. The optical turn assembly has a first optical port that is connected to the second end of the optical waveguide in an orientation aligned with a device-side connection axis, a second optical port that is oriented to communicate optically with the optoelectronic device along a device communication axis substantially intersecting the device-side connection axis, and an optical turn system that is operable to guide light along a path between the first optical port and the second optical port.

Abstract: An improved elastomeric material is described comprising an essentially noncross-linkable amorphous copolymer of tetrafluoroethylene (TFE) and perfluoromethyl vinyl ether (PMVE) which is both a thermoplastic and exhibits exceptional mechanical properties. This material is particularly suitable for use in ultra-clean environments, and particularly for use in an implantable device, since it does not contain contaminants that previous thermoset TFE/PMVE copolymers have required. Among the improved properties of the present invention are excellent biocompatibility, high matrix tensile strength, high clarity, high abrasion resistance, high purity, adequate elasticity, and ease of processing due to the thermoplastic, and noncross-linkable structure of the copolymer. The material of the present invention is also a high strength bonding agent particularly suited for bonding porous PTFE to itself or to other porous substances at room or elevated temperatures.

Abstract: Systems and methods for dynamically limiting total colorant coverage in multi-colorant rendering. Two polyhedra are defined: one contains all the colors that exceed the total colorant limit, and another is within the colorant limit that contains the results of the colorant limitation process. Data is received to identify a specified contone color, which is processed to decide whether it is inside one of the polyhedra. If the specified contone color is not within either polyhedra, the specified contone color is used in the rendering process. Alternatively, if the specified contone color is within one of the polyhedra, the value representing the specified contone color is compressed into the second polyhedra volume to obtain a resultant contone color that is used in the rendering process.

Abstract: Ophthalmic compositions include an ophthalmically acceptable carrier component, for example, an aqueous-based carrier, and a plurality of polyanionic component portions having different molecular weights. In one embodiment, the polyanionic component includes a first polyanionic component portion having a first molecular weight; and a second polyanionic component portion having a different second molecular weight. Each of the first and second polyanionic component portions is present in an amount effective to provide lubrication to an eye when the composition is administered to an eye. Methods of making and using such compositions are also disclosed.

Abstract: A liquid comprising a therapeutically effective concentration of a cyclosporin and a vitamin E tocopherol polyethylene glycol succinate, wherein said liquid is an aqueous solution, and wherein no hydrophilic organic solvent is present at a concentration greater than half of that of the cyclosporin is also disclosed herein. A composition comprising a therapeutically effective concentration of cyclosporin A and an effective amount of a vitamin E tocopherol polyethylene glycol succinate, wherein said composition is an aqueous liquid solution which is intended for ophthalmic use, and wherein no hydrophilic organic solvent is present at a mass concentration greater than or equal to that of the cyclosporin, is disclosed herein.